Canaccord Genuity analyst John Newman maintained a Hold rating on Merus today and set a price target of $97.00. The company’s shares closed yesterday at $94.83.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Newman covers the Healthcare sector, focusing on stocks such as Delcath Systems, Regeneron, and Arcellx Inc. According to TipRanks, Newman has an average return of -0.9% and a 38.38% success rate on recommended stocks.
In addition to Canaccord Genuity, Merus also received a Hold from Needham’s Ami Fadia in a report issued yesterday. However, on September 29, BMO Capital maintained a Buy rating on Merus (NASDAQ: MRUS).
MRUS market cap is currently $7.19B and has a P/E ratio of -17.13.
Read More on MRUS:
Disclaimer & DisclosureReport an Issue
- Oppenheimer positive on CytomX after Merus colon cancer data
- Hold Rating on Merus’s Petosemtamab: Awaiting More Data for Colorectal Cancer Efficacy
- Merus announces initial interim data from phase 2 trial of petosemtamab
- Cautious Optimism: Hold Rating on Merus Amid Anticipation of Phase II Data Presentation and Genmab Acquisition
- Genmab price target raised to $49 from $46 at Truist
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
